Načítá se...
Building on the promise of cancer vaccines for solid tumors
A novel telomerase vaccine (INVAC-1) has been evaluated in a phase I clinical trial (n=26). It induced CD8(+) and CD4(+) T cell responses and reduced circulating regulatory T cells. The findings support further development, especially in combination with vaccine adjuvants, plus therapies to increase...
Uloženo v:
| Vydáno v: | Clin Cancer Res |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7002281/ https://ncbi.nlm.nih.gov/pubmed/31796513 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-19-3206 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|